Search

Researchers at the Division of Nephrology have found that JP4-039, a compound that targets mitochondria and scavenges reactive oxygen species, can mitigate cisplatin-induced acute kidney injury in mice. The study showed that JP4-039 treatment reduced renal dysfunction, histopathological changes, and tubular injury markers in mice injected with cisplatin. Additionally, JP4-039 suppressed lipid peroxidation, oxidative stress, and cytokine overproduction, indicating its potential as a therapeutic agent for cisplatin-induced kidney injury. [Extracted from the article]

A recent study conducted at Jinan University in Guangzhou, China, focused on improving the solubility and stability of the antitumor drug cisplatin through supramolecular chemistry. By forming a complex with 18-crown-6, researchers were able to enhance the solubility and stability of cisplatin, leading to improved therapeutic efficacy in cancer treatment. The study utilized various analytical techniques to confirm the effectiveness of the cisplatin-18-crown-6 complex in enhancing the drug's antitumor activity. This research offers a promising strategy for enhancing the clinical application of cisplatin in cancer therapy. [Extracted from the article]

The article discusses a clinical trial, NCT06731478, evaluating the efficacy and safety of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) combined with other treatments versus standard chemotherapy for HER2-positive gastric or gastroesophageal junction cancer. The trial aims to assess progression-free survival and overall survival in participants with unresectable, locally advanced, or metastatic tumors. The study involves multiple arms with different treatment combinations and is expected to enroll 726 participants, with a completion date set for 2030. [Extracted from the article]

A patent has been issued for regimens, compositions, and methods involving capsaicin and TNF-alpha inhibitors to address hearing loss caused by various factors such as aging, exposure to noise, and ototoxic agents like cisplatin. The patent aims to provide treatments that can ameliorate cisplatin-induced ototoxicity and other side effects, as well as restore hearing sensitivity levels in individuals with reduced hearing capacity. The compositions include a TRPV1 agonist like capsaicin and a TNF-alpha inhibitor like etanercept, which can be administered through various routes to improve hearing in subjects. This patent addresses the urgent unmet need for viable treatment options and preventative measures to reduce noise-induced hearing loss, especially among veterans and individuals in occupations where hearing is critical. [Extracted from the article]

A recent study conducted at the University of Colorado Anschutz Medical Campus focused on the regulation of volume-regulated anion channels and their impact on sensitivity to platinum chemotherapy in various cancer types. The research highlighted the role of the puromycin-sensitive aminopeptidase NPEPPS in controlling cisplatin import into cells, affecting cisplatin response across different cancer types. The findings suggest that targeting NPEPPS could potentially improve outcomes for cancer patients, while also shedding light on intracellular mechanisms with implications beyond cancer treatment. The study was published in Science Advances and can be accessed for further information. [Extracted from the article]

A study conducted at the Third Hospital of Shanxi Medical University in China explored the protective effects of linarin (LIN) against cisplatin-induced nephrotoxicity in male Wistar rats. The research found that LIN administration helped enhance renal function by reducing kidney weight, blood urea nitrogen (BUN) and creatinine (Cr) levels, oxidative stress indicators, and inflammatory markers. The study suggests that LIN could be used to protect kidneys from damage caused by cisplatin therapy, potentially benefiting patients at risk of nephrotoxicity. The findings were published in Pharmacognosy Magazine in 2024. [Extracted from the article]

A study conducted by Kyungpook National University in South Korea explored the potential of sodium phenylbutyrate (4-PBA) in preventing cisplatin-induced acute kidney injury (AKI). The research involved administering 4-PBA to a murine model before and after cisplatin challenge, evaluating tubular injury, serum BUN and creatinine levels, inflammatory markers, apoptosis, mitochondrial function, and the expression of pyruvate dehydrogenase kinase 4 (Pdk4). The study found that 4-PBA effectively prevented AKI by suppressing Pdk4 expression, without interfering with the anti-cancer efficacy of cisplatin. [Extracted from the article]

A recent study conducted at University Hospital Zurich explored the efficacy of combining intracavitary cisplatin-fibrin with hemithoracic irradiation in treating pleural mesothelioma in rats. The research found that this combination treatment resulted in improved tumor control compared to single treatments, with minimal short-term side effects observed. The study suggests that localized treatment after tumor resection in pleural mesothelioma may enhance local tumor control and delay tumor growth. For more information, the full article can be accessed at https://doi.org/10.1016/j.xjon.2024.07.024. [Extracted from the article]

During a shortage of generic platinum chemotherapy drugs cisplatin and carboplatin in early 2023, a study found that there was no increase in mortality rates among patients with advanced cancer compared to the previous year. Prescription rates for the two drugs fell less than three percent overall, with a 15.1 percent decrease at the peak of the shortage. Alternative medications, such as immune checkpoint inhibitors and targeted therapy, helped mitigate the crisis, but the study did not assess potential drawbacks of these alternatives. The FDA has resolved the cisplatin shortage, while carboplatin remains on the shortage list, although prescribing levels have returned to normal. [Extracted from the article]

A recent study conducted at Anhui Normal University in Wuhu, People's Republic of China, focused on developing a new method for imaging hypochlorous acid (HOCl) in living cells and brains of Alzheimer's disease (AD) mice. The study introduced J-aggregation-induced organic fluorescent dots with large Stokes-shift, showing promise as an imaging probe to understand and reveal AD pathologies. Funded by the National Natural Science Foundation of China, this research highlights the importance of monitoring biomarker levels in brain tissues to track the early onset and progression of AD. [Extracted from the article]

A study conducted by the CSIR - Indian Institute of Chemical Biology in West Bengal, India, explored the effects of ellagic acid (EA) on cancer stem-like cells (CSLCs) and its ability to overcome cisplatin resistance. The research found that EA treatment reduced the stem-like phenotypes in cancer cells, leading to decreased cell survival and self-renewal potential in ovarian and lung CSLCs. Additionally, EA induced DNA damage and apoptosis in CSLCs by targeting mitochondrial function, making it a potential therapeutic option for cancer management, either alone or in combination with other chemotherapeutic drugs. [Extracted from the article]

Researchers at Sichuan Cancer Hospital in China have found that all-trans retinoic acid (ATRA) can sensitize epithelial ovarian cancer (EOC) cells to PARP inhibition after exposure to cisplatin. This combination therapy showed promising results in reducing PARPi resistance-associated EOC cells and improving survival rates in EOC-bearing mice. The study suggests that ATRA in conjunction with PARPi could be a potential maintenance therapeutic strategy for EOC patients. The research was published in Molecular Cancer Therapeutics and can be accessed for free online. [Extracted from the article]

Researchers at Soochow University in Suzhou, China, conducted a study on the cytotoxic effects of natural and synthetic cannabinoids on human ovarian cancer cells. They found that cannabidiol (CBD) and its derivatives showed promising antiproliferative effects, with two derivatives showing enhanced cytotoxicity compared to CBD alone. The study also explored the synergistic effects of CBD derivatives with the chemotherapeutic agent cisplatin, suggesting potential for cannabinoid-based adjuvant agents in ovarian cancer treatment. This research provides insight into the development of new therapies for managing ovarian cancer. [Extracted from the article]

A new small-molecule inhibitor, VWK147, targeting the C-terminal dimerization of HSP90 has been developed to combat chemoresistance in urothelial cancer cells. This inhibitor induces cell death in both cisplatin-sensitive and cisplatin-resistant cells without triggering a cytoprotective heat shock response. Additionally, VWK147 in combination with mTOR inhibition synergistically kills cancer cells, potentially offering a promising option to improve anti-cancer therapies and overcome treatment resistance. [Extracted from the article]

Researchers from Binzhou Medical University in China conducted a study on the effects of the Fscn2 gene on cisplatin-induced hearing impairment in mice. The study found that mice lacking the Fscn2 gene experienced more severe hearing loss and cochlear cell degeneration when exposed to cisplatin compared to mice with the gene. The research concluded that FSCN2 plays a role in reducing cisplatin-induced ototoxicity by inhibiting cell apoptosis. This study provides valuable insights into potential mechanisms for preventing hearing impairment caused by cisplatin therapy. [Extracted from the article]

A recent preprint abstract suggests that vitamin C at millimolar concentrations can inhibit the generation of hypochlorous acid by myeloperoxidase, impacting the growth and viability of Jurkat cells. The oxidation products of vitamin C interact with specific thiol proteins, indicating potential implications for cancer treatment and diseases related to neutrophil activation. The study highlights the importance of maintaining pharmacological levels of vitamin C in the bloodstream for beneficial effects, potentially through oxidation facilitation treatments. [Extracted from the article]

Researchers from Ladoke Akintola University of Technology conducted a study on the effects of Isothiocyanato-4-methylsulfonylbutane (SFN) on germ cell apoptosis in testicular toxicity induced by Cisplatin (CP). The study involved male and female rats treated with different doses of CP, SFN, and vitamin C for 56 days. The results showed that SFN intervention increased BCL-2 expression, protected sperm chromatin condensation, and decreased sperm DNA fragmentation (SDF) and BAX expression, suggesting that SFN may protect against CP-induced apoptosis. The study was published in Aspects of Molecular Medicine in 2024. [Extracted from the article]

Recent research from Minia University has highlighted the potential therapeutic effects of bee drone milk-fortified soymilk on cisplatin-induced testicular toxicity. The study evaluated the impact of this fortified soymilk on male Wistar rats, showing improvements in antioxidant capacity, sperm motility, hormone levels, and testicular function. The findings suggest that bee drone milk-fortified soymilk could be a promising functional food for alleviating cisplatin-induced testicular toxicity. [Extracted from the article]

The article discusses a study on using the gold complex auranofin to enhance the effectiveness of cisplatin in treating platinum-resistant epithelial ovarian cancer cells. The research aims to combat recurrent stages of ovarian cancer by repurposing auranofin, which has shown potential in inducing apoptosis and DNA damage in resistant cells. The study suggests that combining auranofin with cisplatin could be a promising second-line therapy for recurrent epithelial ovarian cancers. [Extracted from the article]

The research from the University of Texas explores the impact of platinum chemotherapies on hematopoietic stem cells and the risk of therapy-related myeloid neoplasms. The study found that oxaliplatin treatment was associated with a significantly lower risk of therapy-related myeloid neoplasms compared to cisplatin or carboplatin treatments. While oxaliplatin promoted the expansion of mutated stem cells, it induced fewer somatic mutations, providing insights into mitigating the risk of therapy-related myeloid neoplasms. [Extracted from the article]

A recent study from Wright State University explores the role of TIP60 in enhancing cisplatin resistance in squamous cell carcinoma (SCC) by regulating DNp63a acetylation. The research suggests that TIP60 contributes to the failure of platinum-based drugs in SCC by stabilizing DNp63a and promoting cell proliferation while inhibiting apoptosis. The findings indicate that inhibiting TIP60 may be beneficial in overcoming cisplatin resistance in SCC and other epithelial cancers. This study provides critical insights into the mechanisms underlying cisplatin resistance in SCC and offers potential therapeutic strategies for future treatment. [Extracted from the article]

A recent study conducted at Ohio State University Comprehensive Cancer Center examined the impact of weekly cisplatin cycles on outcomes for patients undergoing chemoradiation for head and neck cancer. The study found that patients who missed weekly cisplatin cycles had worse overall survival and progression-free survival compared to those who completed 7 to 8 cycles. Notably, patients with p16-negative tumors experienced lower overall survival when missing cisplatin cycles, while those with p16-positive tumors did not show significant differences in overall survival. Cytopenia was identified as the most common reason for cisplatin interruption. [Extracted from the article]

A clinical trial, NCT06718257, is being conducted to assess the effectiveness and safety of GP/GEMOX combined with PD-1/L1 inhibitors and TKI agents in patients with advanced cholangiocarcinoma. The study aims to guide clinical practice by collecting relevant clinical data from patients treated with these therapies. The trial is recruiting 300 participants in China and is set to be completed by January 31, 2025. [Extracted from the article]

A recent study from Hanyang University College of Medicine highlights the evolving treatment landscape for metastatic urothelial carcinoma (mUC). While cisplatin-based chemotherapy has been the standard first-line treatment, up to 50% of patients may be ineligible for this therapy, leading to the emergence of immune checkpoint inhibitors (ICIs) as an alternative. The combination of enfortumab vedotin (EV) and pembrolizumab has shown promising results as a first-line treatment for cisplatin-ineligible patients, offering improved survival rates. This research aims to guide clinical decision-making and therapeutic strategies for patients with mUC, emphasizing the increasing relevance of ICI-containing regimens in frontline cancer care. [Extracted from the article]

Researchers at Wayne State University have conducted a Phase II trial evaluating the efficacy of epcoritamab with GDP salvage chemotherapy in patients with relapsed refractory large B-cell lymphoma. The study aims to improve outcomes for patients awaiting CAR T-cell therapy by providing effective bridging therapy. The trial design includes administering epcoritamab and GDP in the outpatient setting, with the primary endpoint being complete remission rate. This research offers potential insights into novel treatment approaches for patients with relapsed refractory large B-cell lymphoma. [Extracted from the article]

A randomized controlled trial is being conducted to assess the effectiveness and safety of toripalimab combined with GemCis as preoperative neoadjuvant therapy for resectable Intrahepatic Cholangiocarcinoma (ICC) with a high risk of recurrence. The trial, NCT06721286, aims to evaluate the 1-year recurrence-free survival rate and other outcomes in patients with ICC. The study is being conducted by Tianjin Medical University Cancer Institute and Hospital in China, with recruitment ongoing and an enrollment target of 70 participants. [Extracted from the article]

A prospective Phase II study is being conducted to evaluate the safety and efficacy of concurrent chemoradiotherapy combined with toripalimab and surufatinib in treating limited-stage small cell lung cancer (LS-SCLC). The study aims to explore the potential benefits of incorporating surufatinib into the treatment regimen to enhance survival in LS-SCLC patients. The trial, NCT06719700, involves administering chemotherapy, immunotherapy, and an angio-immuno kinase inhibitor, along with radiotherapy and consolidation therapy with toripalimab and surufatinib. Recruitment for the study is ongoing, with a primary completion date set for November 29, 2028. [Extracted from the article]

A clinical trial, NCT06728618, is being conducted to evaluate the effectiveness and safety of a combination therapy involving immunotherapy (Tislelizumab), targeted therapy (Cetuximab), and chemotherapy (Cisplatin and Nab-paclitaxel) for locally recurrent oral and oropharyngeal squamous cell carcinoma. The trial aims to assess the treatment's impact before and after salvage surgery, with continued immunotherapy and targeted therapy post-surgery. The study focuses on patients with resectable recurrent oral and oropharyngeal squamous cell carcinoma, aiming to improve outcomes through a comprehensive treatment approach. [Extracted from the article]

A new study conducted by a researcher from the Chinese Academy of Medical Sciences explores the combination of Mitoxantrone Hydrochloride Liposome with Gemcitabine, Cisplatin, and Dexamethasone in patients with relapsed or refractory Peripheral T Cell Lymphoma (PTCL). The study aims to investigate the safety and efficacy of this combination regimen, with promising results in terms of efficacy and manageable safety profiles. The research is ongoing, with a phase II study planned to confirm and validate the findings. The study provides valuable insights into potential novel therapeutic strategies for PTCL patients. [Extracted from the article]

A recent study from Guangzhou Medical University in China explores the role of the deubiquitinase Usp44 in enhancing cisplatin chemosensitivity in neuroblastoma. The research highlights the molecular mechanisms by which Usp44 regulates cisplatin sensitivity and its impact on neuroblastoma patient prognosis. The findings suggest that the USP44-STUB1-LRPPRC axis could be a potential target for neuroblastoma therapy and prognostication. This peer-reviewed study provides valuable insights into neuroblastoma chemoresistance and potential therapeutic targets. [Extracted from the article]

A recent study conducted at the First Hospital of Jilin University in Changchun, People's Republic of China, focused on evaluating the effectiveness of different hyperthermic intraperitoneal chemotherapy (HIPEC) drug regimens in treating advanced gastric cancer. The study found that HIPEC treatment, particularly with the cisplatin regimen, showed benefits in overall survival and reducing peritoneal recurrence without significant postoperative morbidity. While no single HIPEC regimen demonstrated clear benefits across all outcomes, the cisplatin regimen performed well in multiple aspects, suggesting its potential for further research and clinical application. This research provides valuable insights into optimal treatment approaches for advanced and peritoneal metastatic gastric cancer. [Extracted from the article]

Researchers at Yunnan University in Kunming, China, have developed six polypyridyl Ru(II) complexes for dual photodynamic and sonodynamic therapy (PDT/SDT) to combat cisplatin-resistant non-small cell lung cancer. These complexes have shown promising results in generating singlet oxygen and superoxide anion, inducing apoptosis and ferroptosis in cancer cells. The study highlights the potential of using single-molecule sensitizers for synergistic PDT/SDT in treating drug-resistant tumors, particularly in hypoxic environments. This research, funded by various organizations, provides valuable insights into innovative cancer treatment strategies. [Extracted from the article]

Researchers at Fudan University in Shanghai, China, have developed a novel nanocomposite that allows for non-invasive delivery of dexamethasone to reverse hearing loss induced by cisplatin therapy. The nanocomposite, which is responsive to near-infrared light, enhances drug permeation and controls drug release, leading to efficient delivery of dexamethasone to the inner ear. The study demonstrates the effectiveness of this approach in recovering hearing loss, protecting hair cells, and alleviating damage to synaptic ribbons. This research provides valuable insights into local drug delivery for inner ear conditions. [Extracted from the article]

Researchers from Khon Kaen University conducted a study on the anticancer activities of peanut testa extract in combination with cisplatin and 5-fluorouracil against cholangiocarcinoma cells. The study found that the peanut extract inhibited the proliferation of cancer cells more effectively than noncancer cells and induced apoptosis and cell cycle arrest. The researchers concluded that the peanut extract may be an effective synergistic agent with cisplatin and 5-fluorouracil for cholangiocarcinoma chemotherapy, warranting further clinical examination. [Extracted from the article]

A recent study conducted at the First Affiliated Hospital in Shandong, China, explored the use of gliquidone, an antidiabetic drug, in combating cisplatin-resistant human lung adenocarcinoma. The research highlighted the role of glutathione S-transferase pi-1 (GSTP1-1) in drug resistance and demonstrated that gliquidone could inhibit tumor cell proliferation by suppressing GSTP1-1 expression. The study suggested that gliquidone may have potential as an adjunct therapy for cisplatin-resistant lung cancer, offering a new avenue for treatment. [Extracted from the article]

Research conducted at the Universidad Autonoma de Tlaxcala focused on the effects of N-acetylcysteine (NAC) on cognitive impairment and muscular weakness induced by cisplatin in female rats. The study found that NAC administration prevented long-term memory deficits and reduced muscle strength caused by cisplatin treatment. NAC was shown to mitigate the side effects of cisplatin by improving redox imbalance and modulating kynurenic acid levels in the brain. The findings suggest potential therapeutic benefits of NAC in reducing chemo-brain and muscle weakness associated with cisplatin treatment. [Extracted from the article]